Summary: The paper cites the definition of severe asthma consistent with the position of the WHO and discusses the most common problems in its treatment and the availability of biological therapy for patients who have not achieved disease control using standard therapy. The paper contains information about the possibility of primary care physicians and specialists referring patients to centers conducting treatment with omalizumab and mepolizumab as part of NFZ (Polish National Health Fund) services.